Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Japan Govt to Push Ahead with Off-Year Survey, Considering COVID-19 Impact to Decide on Re-Pricing
Japan will be pressing ahead after all with a drug price survey this autumn towards “off-year” re-pricing in FY2021, while looking at the impact of COVID-19 to actually decide on what to do with the price revision itself, informed sources…
To read the full story
Related Article
- With Equivocal Honebuto Wording, Off-Year Re-Pricing Debate Delayed Until Year-End
July 30, 2020
- 2020 Policy Blueprint Restresses Efforts on COVID-19 Meds/Vaccines; Drug Price Survey Up for Discussion on July 22
July 20, 2020
- Japan Govt Adopts 2020 Honebuto Policy, Drug Price Survey to Be Conducted This Autumn
July 17, 2020
- Japan Govt to Tweak Honebuto Text for Off-Year Re-Pricing, but Still Holds to Original Plan
July 15, 2020
- LDP Lawmakers Irked as Govt Stands Fast on Off-Year Re-Pricing/Survey Plan; Honebuto Text Tweak Unclear
July 10, 2020
- Original Plan Remains Unchanged for Off-Year Drug Re-Pricing, Survey: Minister
July 9, 2020
- Wholesaler Group Makes Emergency Plea against Off-Year Drug Price Survey
July 7, 2020
- Japan Govt Likely to Stick to 2020 Off-Year Drug Re-Pricing Plan in Honebuto Paper
July 6, 2020
- Ruling Parties Call for Careful Discussions on Off-Year Drug Re-Pricing
July 3, 2020
- LDP’s Coronavirus Task Force Calls for Caution in Off-Year Re-Pricing Debate
June 26, 2020
- LDP Pharma Study Group Submits Proposal, Says Off-Year Re-Pricing Should Be Delayed
June 19, 2020
REGULATORY
- CEA Expansion Could Make Drug Price Premiums a Liability: JPMA Official
October 16, 2026
- Nipro’s Stemirac Nears 1st Full Nod Conversion for Regenerative Therapy
October 16, 2026
- Japan Set to Compile Support Measures to Secure MCMs by Year-End
October 15, 2026
- Japan to Weigh Necessary Measures for FY2027 Revision: PM
October 15, 2026
- Japan Eyes Multi-Year Funding to Secure MCMs: Takaichi
October 14, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…